SYK · Stryker
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $330
Note written ·
Price against the kill line
3.8% clear of its kill line on the 17 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $330.00, set on 15 November 2026. The shares are down 6.3% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $330, over the 200-day moving average and the $325.87 close of 6 November 2026, which would show the shares leading again; or a first 2027 outlook, in the late-January 2027 report, calling for organic sales growth above 2026's 6.5%–7.0% range.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Stryker makes and sells medical devices to hospitals and surgery centres: hip and knee implants, Mako surgical robots, trauma and spine products, surgical equipment, beds and neurovascular devices. It earns money from implant and disposable sales plus capital equipment. Revenue was $6,520 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 29 October 2026 Stryker cut its 2026 organic sales growth outlook to 6.5%–7.0% and adjusted EPS to $14.80–$14.90, citing a market-wide US hip and knee procedure slowdown (company 8-K).
- What follows for the company
- Sales growth slowed to 7.6% in the September quarter, but adjusted operating margin rose 60 basis points to 26.2%; a $293 million goodwill impairment cut the reported operating margin to 15.9%.
- What follows for its customers, suppliers and competitors
- Zimmer Biomet (ZBH), Smith & Nephew (SNN) and Johnson & Johnson (JNJ) sell into the same slowing hip and knee market; the CMR Surgical stake moves Stryker toward Intuitive Surgical (ISRG) in soft-tissue robotics.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 30 October 2026) the shares trade at 32.5 times earnings, 23.8 times EV/EBIT and 4.9 times sales, for an enterprise value of $129,536 million. That holds only if revenue keeps growing near the 7.6% of the latest filed quarter while the operating margin, 15.9% that quarter after an impairment, returns toward the 25.2% of the June quarter.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 30 October 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 6,520
- Revenue, change on a year (%)
- +7.6
- Gross margin (%)
- 65.2
- Operating margin (%)
- 15.9
- Free cash flow, four quarters ($M)
- 4,573
- Net cash, cash less debt ($M)
- −11,659
- Price to earnings (×)
- 33.4
- Enterprise value to sales (×)
- 5.0
All filed numbers
What Stryker reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 6,520 | +7.6 | 65.2 | 15.9 |
| first filed | 6,589 | +9.4 | 68.3 | 25.2 |
| first filed | 6,020 | +2.6 | 63.3 | 15.5 |
| first filed | 7,171 | +11.4 | 64.5 | 25.2 |
| first filed | 6,057 | +10.2 | 63.6 | 18.7 |
| first filed | 6,022 | +11.1 | 63.8 | 18.5 |
| Pre-tax income ($M) | 997 |
| Net income ($M) four quarters: 3,623 | 753 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −0.5 |
| Operating cash flow ($M) | 5,446 |
| Capital spending ($M) | 873 |
| Free cash flow ($M) | 4,573 |
| Cash and short-term investments ($M) | 3,271 |
| Debt ($M) | 14,930 |
| Net cash, cash less debt ($M) | −11,659 |
| Deferred revenue ($M) +2.2% on a year | 960 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 3,693 |
| Inventory ($M) | 5,747 |
| Shareholders' equity ($M) including non-controlling interests | 23,457 |
| Market value ($M) | 120,885 |
| Enterprise value, market value plus net debt ($M) | 132,544 |
| Enterprise value to sales (×) | 5.0 |
| Enterprise value to operating income (×) | 24.4 |
| Price to earnings (×) | 33.4 |
| Price to book value (×) | 5.2 |
| Free-cash-flow yield (%) | 3.8 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 1.8% of shares outstanding sold short, 2.2 days of average trading to cover, +16.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
The thesis
Stryker's shares are more likely to lag the S&P 500 over the next three months. The company cut its 2026 organic sales growth outlook to 6.5%–7.0% on 29 October 2026 because hip and knee procedures slowed across the US market, and nothing dated yet shows that slowdown ending. The fourth-quarter report and first 2027 outlook, expected in late January 2027 under a new chief executive, decide the case.
Third-quarter sales grew 7.7% to $6.5 billion (company 8-K, 29 October 2026), but US knees grew 1.3% to $458 million and US hips fell 0.6% to $277 million. Chief executive Kevin Lobo said on the call that "it is now clear that there is a market slowdown." He tied it to higher insurance premiums, deductibles and pre-authorization denials (MedTech Dive, 30 October 2026). A slowdown driven by patients' costs is unlikely to reverse within one quarter. Management also told analysts that fourth-quarter organic growth should be broadly comparable to the third quarter's, according to Zacks' summary of the call.
The rating is Low because the shares still carry a premium multiple while growth slows. At the 13 November 2026 close they trade at 32.5 times earnings and 23.8 times enterprise value to operating profit (EV/EBIT). Profit is holding up better than sales: adjusted earnings per share (EPS) rose 10.3% to $3.52 and the adjusted operating margin widened 60 basis points to 26.2% (8-K, 29 October 2026).
Bullish and bearish views on Stryker Corporation
The bull case on Stryker Corporation (SYK), in brief: margins absorb the slower sales. The bear case: the joint replacement market has slowed.
Bull case
- Margins absorb the slower sales. Third-quarter gross margin was 65.2%, against 63.6% a year earlier (10-Q filed 30 October 2026). Full-year adjusted EPS guidance of $14.80–$14.90 was trimmed only modestly (8-K, 29 October 2026).
- The rest of the company still grows. MedSurg and Neurotechnology sales rose 9.2% to $3.7 billion in the third quarter, against 5.7% for Orthopaedics (8-K, 29 October 2026).
- Analysts mostly read the slowdown as delayed demand. Piper Sandler raised its target to $350 from $325 and kept Overweight on 9 November 2026 after a surgeon survey, still expecting mid-single-digit procedure growth through 2027. JPMorgan kept Overweight with a $340 target on 31 October 2026.
- Cash generation is large. Free cash flow was $4,573 million over the four quarters to 30 September 2026, and the diluted share count fell 0.5% from a year earlier (10-Q filed 30 October 2026).
- Soft-tissue robotics is a new route to growth. Stryker invested $400 million in CMR Surgical in October 2026 and became exclusive US distributor of its robot; Lobo said Stryker hopes eventually to buy the company (MedTech Dive, 30 October 2026).
Bear case
- The joint replacement market has slowed. US hips fell 0.6% and US knees grew 1.3% in the third quarter (8-K, 29 October 2026), and management called the slowdown market-wide.
- The outlook was cut, not trimmed. Organic growth guidance fell to 6.5%–7.0% on 29 October 2026, and the lower bound of the earlier range was 8% or higher.
- Self-inflicted problems add to the market slowdown. A cyberattack earlier in 2026 and a new software system disrupted orthopaedics selling (MedTech Dive, 30 October 2026). A $293 million goodwill impairment cut reported EPS 11.7% to $1.96 in the third quarter (8-K, 29 October 2026).
- A director keeps selling. Director Ronda E. Stryker sold 550,000 shares at an average $325.32 on 6 November 2026, after selling 350,000 at an average $336.50 on 18 August 2026 and 19 August 2026 (SEC Form 4 filings). A common market view is that steady selling by a large holder weighs on a stock's price.
- Leadership changes during the reset. Lobo steps down at the end of 2026 after 15 years, and chief operating officer Spencer Stiles takes over in January 2027 (MedTech Dive, 30 October 2026). The first 2027 outlook will come from the new chief executive.
- Debt is higher than cash. Debt was $14,930 million against $3,271 million of cash and short-term investments at 30 September 2026 (10-Q filed 30 October 2026).
Price setup
The shares closed at $309.64 on 13 November 2026, 20.5% below the 52-week intraday high of $389.33 set on 2 March 2026. They are down 6.3% over three months. The 52-week closing low is $269.75, set on 24 September 2026.
The last close sits above the 50-day moving average of $291.95 and below the 200-day moving average of $320.42 (adjusted daily closes, as of 13 November 2026). The 200-day average is the nearest level above the price that the case turns on.
The shares closed lower in each of the six sessions from $325.87 on 6 November 2026 to $309.64 on 13 November 2026. The fall began on the day of the 550,000-share director sale. It continued through Piper Sandler's target increase on 9 November 2026. For scale, the standard deviation of 63-session returns across liquid US stocks was 27% in 2026, so a 20% fall from a peak is common among US stocks this year.
Catalysts ahead
- ~1 January 2027 (est.): Spencer Stiles succeeds Kevin Lobo as chief executive; Quest Diagnostics chief Jim Davis joins the board. The new chief executive sets the first 2027 outlook, which could reset expectations lower or confirm the slowdown as a delay.
- ~28 January 2027 (est.): Fourth-quarter 2026 results and first 2027 guidance. US hip and knee growth and the 2027 organic growth outlook show whether the procedure slowdown is passing or lasting; a 2027 range above 2026's 6.5%–7.0% would undercut the lag call.
- ~5 February 2027 (est.): Zimmer Biomet fourth-quarter 2026 results. A peer read on whether US knee and hip volumes are recovering across the market Stryker called slowing.
What would change the view
A daily close above $330, over the 200-day moving average and the $325.87 close of 6 November 2026, which would show the shares leading again; or a first 2027 outlook, in the late-January 2027 report, calling for organic sales growth above 2026's 6.5%–7.0% range.
What it trades with
Stryker trades with the large orthopaedic device makers that sell into the same US hip and knee market: Zimmer Biomet (ZBH), Smith & Nephew (SNN) and Johnson & Johnson's (JNJ) DePuy Synthes. Lobo described the third-quarter slowdown as market-wide on 29 October 2026. That makes these peers' fourth-quarter knee and hip numbers, due in early 2027, a direct cross-check on Stryker's own.
The case also depends on US patients' out-of-pocket costs. Lobo tied the slowdown to insurance premiums, deductibles and pre-authorization denials (MedTech Dive, 30 October 2026), so news on 2027 insurance plan costs bears on elective procedure volumes. The CMR Surgical stake puts Stryker closer to competing with Intuitive Surgical (ISRG) in soft-tissue robotics.
The evidence, claim by claim (8)
- Third-quarter 2026 net sales rose 7.7% to $6.5 billion on both a reported and an organic basis; adjusted EPS rose 10.3% to $3.52 and reported EPS fell 11.7% to $1.96. Stryker third-quarter 2026 results, 8-K exhibit 99.1 · as of
- US knee sales grew 1.3% to $458 million and US hip sales fell 0.6% to $277 million in the third quarter of 2026. Stryker third-quarter 2026 results, 8-K exhibit 99.1 · as of
- Stryker set full-year 2026 organic sales growth guidance at 6.5%–7.0% and adjusted EPS guidance at $14.80–$14.90. Stryker third-quarter 2026 results, 8-K exhibit 99.1 · as of
- Stryker recorded a $293 million goodwill impairment in the third quarter of 2026; the adjusted operating margin was 26.2%, up 60 basis points. Stryker third-quarter 2026 results, 8-K exhibit 99.1 · as of
- Kevin Lobo said 'it is now clear that there is a market slowdown' in hips and knees, tying it to US insurance premiums, deductibles and pre-authorization denials. MedTech Dive, 'Stryker lowers 2026 guidance after slowdown in hip, knee procedures' · as of
- Kevin Lobo steps down as chief executive at the end of 2026; chief operating officer Spencer Stiles takes over in January 2027. MedTech Dive, 30 October 2026 · as of
- Director Ronda E. Stryker sold 550,000 shares in the open market at an average $325.32 on 6 November 2026. SEC Form 4 filed 9 November 2026 · as of
- Piper Sandler kept Overweight on Stryker and raised its price target to $350 from $325 after a surgeon survey. Piper Sandler note reported by Benzinga, 9 November 2026 · as of
Sources
- STRYKER CORP - Form 8-K - FY2026 · sec.gov ·
- Stryker lowers 2026 guidance after slowdown in hip, knee procedures · finance.yahoo.com ·
- SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook · zacks.com
- Stryker stock: Piper Sandler raises target after surgeon survey · ad-hoc-news.de
Related · shared themes
ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter…
AXGN
Axogen
Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest…
CSTL
Castle Biosciences
Castle Biosciences is modestly more likely than not to beat the S&P 500 over three months, because its TissueCypher test drove 24% revenue…
DXCM
DexCom
Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased…